BSF Enterprise PLC 3D Bio-Tissues enters partnership with New Harvest (1329K)
19 Dezembro 2022 - 4:00AM
UK Regulatory
TIDMBSFA
RNS Number : 1329K
BSF Enterprise PLC
19 December 2022
19 December 2022
BSF Enterprise PLC
("BSF" or the "Company")
3D Bio-Tissues enters partnership with New Harvest
BSF (LSE:BSFA), an investment company focused on unlocking the
next generation of biotech solutions and the development of
lab-grown tissues, is pleased to announce that its 100% owned
subsidiary, 3D Bio-Tissues Ltd ("3DBT"), has commenced a formal
consulting collaboration with Stichting New Harvest Netherlands
("New Harvest"), a non-profit organisation dedicated to advancing
cellular agriculture, focused on advancing 3DBT's route-to-market
strategy and accelerating the commercialisation of its products
worldwide.
New Harvest will provide 3DBT with a clear and comprehensive
roadmap of the safety and regulatory requirements of animal-free
media, its ingredients and derivatives in the European Union, UK,
and others as time allows. The project is focused on aligning
3DBT's innovative City-mix(TM) cell-boosting supplements with
existing international standards, including regulatory pathways for
chemicals or substances added to food which have previously been
deemed safe by experts.
The project, which will be undertaken over the next 12 months,
will include:
-- Expert analysis on the current regulatory and safety
legislation relating to the manufacture and utilisation of
animal-free media
-- Predicted milestones and corresponding timeframes
-- Defined action points
New Harvest is currently advancing understanding in the safety
of cultivated meat and seafood research in partnership with various
governments and intergovernmental organisations such as the Food
and Agriculture Organization ("FAO") of the United Nations to drive
forward a clear global framework for cultivated meat production
with the overall aim of providing products to a growing market as
well as significantly reducing greenhouse gas emissions from food
production.
Che Connon, Chief Executive of 3D-Bio Tissues, said: "Today's
announcement marks the start of a significant workstream focused on
putting affordable cultivated meat on shelves. New Harvest's
partnerships across government and industry are integral to helping
accelerate breakthroughs in cellular agriculture and laying the
foundations for companies like 3DBT to drive the adoption of our
products on a mass-scale. We look forward to working with them as
we continue to unveil further larger-scale prototypes and the UK's
first lab-grown fillet in the coming months."
Isha Datar, Executive Director of New Harvest, said: "Bringing
together the public and private sectors to advance cellular
agriculture is critical to our collective mission and success. We
are delighted to be working with the team at 3DBT on bringing more
real-world understanding and information on the safety and
regulatory aspects of cell cultured meat and seafood to the public.
Their product and their collaborative approach will be of benefit
to the entire field at large."
For further enquiries, please visit www.bsfenterprise.com or contact:
BSF Enterprise PLC Via SEC Newgate
below
Geoff Baker - Non-Executive Director
Che Connon - Executive Director
----------------------
Shard Capital (Broker)
----------------------
Damon Heath 0203 971 7000
----------------------
SEC Newgate (Financial Communications)
----------------------
Bob Huxford 020 3757 6882
Elisabeth Cowell BSF@secnewgate.co.uk
George Esmond
----------------------
Notes to Editors
BSF Enterprise PLC (BSF) is focused on unlocking the next
generation of biotechnological solutions - using cell-based tissue
engineering to help generate cultivated meat, lab-grown leather, as
well as human corneas, collagen growth and skin substitutes, as
part of a radical transformation to deliver sustainable solutions
across a variety of sectors.
It owns 100% of 3D Bio Tissues Ltd (3DBT), a tissue engineering
company with patent-protected IP that is already producing human
corneas that will help restore vision to millions of people.
Building on this success, it aims to produce the UK's first high
quality lab-grown meat from its laboratory in Newcastle the next 12
months, transforming the meat-production industry towards an
ethical and sustainable practice.
BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as
well as through M&A. It aims to acquire a suite of technologies
that underpins the development of tissue templating for corneas,
meat and leather, and license out the IP to manufacturers,
wholesalers and distributors to help manufacture the products at
scale.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRGPGUGPUPPUQB
(END) Dow Jones Newswires
December 19, 2022 02:00 ET (07:00 GMT)
Bsf Enterprise (LSE:BSFA)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Bsf Enterprise (LSE:BSFA)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025